Market Place
Sourcing Support
Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
26 Jul 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Notification of Major Holdings
09 Jul 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Change of Registered Address
02 Jul 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
09 May 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
01 May 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
30 Apr 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
30 Apr 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
30 Apr 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
29 Apr 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
20 Mar 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Director Share Purchase
19 Feb 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
15 Feb 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
12 Feb 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
17 Jan 2024 //
ACCESSWIRE
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
20 Dec 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
11 Dec 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
21 Nov 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
16 Nov 2023 //
ACCESSWIRE
Former Amryt Pharma Leadership Team join Poolbeg
09 Nov 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented
03 Nov 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
01 Nov 2023 //
ACCESSWIRE
Poolbeg Partners with a Nasdaq-Listed Biopharma
17 Oct 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
29 Sep 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
19 Sep 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Board Appointment
24 May 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
12 Apr 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
30 Mar 2023 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology
16 Jan 2023 //
ACCESSWIRE
Poolbeg Identifies Novel RSV Drug Candidates
21 Dec 2022 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Metabolic Diseases Oral Delivery Licence Signed
14 Dec 2022 //
ACCESSWIRE
Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed
12 Dec 2022 //
ACCESSWIRE
Poolbeg Pharma PLC Announces Capital Markets Day
17 Nov 2022 //
ACCESSWIRE
Poolbeg Pharma PLC Announces AI Programme Yields Novel RSV Drug Targets
08 Nov 2022 //
ACCESSWIRE
